▟ Vinebot intrinsic value, daily

← back

ELV Elevance Health

healthcare · valued with opus medium conviction · deep-dived 2026-10-23

STRONG BUY
Intrinsic value$442.04
Price (at call)$445.28
Margin of safety -0.7%
vs market (rating basis) +50.4%

Blue franchise in a cyclical cost trough; price only works if margins recover to 5.5%.

The story

Elevance is the largest Blue Cross Blue Shield licensee, a scaled managed-care franchise spanning commercial, Medicaid, Medicare Advantage, and a growing Carelon services arm (pharmacy, behavioral, care delivery). Its moat is the exclusive Blue brand in 14 states, local provider network discounts, and scale in claims data. Today it is a mature business going through a cyclical margin trough, hurt by Medicaid redetermination acuity shifts, elevated Medicare Advantage utilization, and ACA risk-pool deterioration. Repricing, benefit cuts, and Carelon mix should restore margins toward the industry's normal mid-single digits, though probably not to past peaks.

Year-1 growth is modest because the company is pruning unprofitable membership and repricing. Over the horizon, growth runs at medical cost trend plus Carelon expansion before settling at 3% terminal, below the 4.95% risk-free rate. Margin recovers from 3.6% TTM to 5.5% over four years, which is below the 2022 peak of 5.4%-plus and in line with long-run managed-care economics. Sales-to-capital of 3.0 reflects a capital-light insurance float model, slightly above the trailing 2.65 as acquisition spending slows. Beta of 0.9 matches the industry anchor, and failure risk is minimal for a firm this size.

Value drivers

Revenue growth (Y1)4.0%
Terminal growth3.0%
Forecast horizon8y
Target operating margin5.5%
Years to target margin4
Sales-to-capital3.00
Beta0.90
Failure probability1.0%
Cost of capital (WACC)8.3%
Terminal WACC8.6%

Valuation bridge

PV of explicit FCFF42.10B
PV of terminal value77.43B
Equity value95.86B
÷ shares → per share$442.04

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 209.16B 4.0% 4.1% 7.23B 2.68B 4.55B 4.20B
2 217.23B 3.9% 4.6% 8.37B 2.69B 5.68B 4.84B
3 225.29B 3.7% 5.0% 9.57B 2.69B 6.88B 5.41B
4 233.34B 3.6% 5.5% 10.83B 2.68B 8.15B 5.92B
5 241.34B 3.4% 5.5% 11.20B 2.67B 8.53B 5.73B
6 249.27B 3.3% 5.5% 11.57B 2.64B 8.92B 5.53B
7 257.10B 3.1% 5.5% 11.93B 2.61B 9.32B 5.33B
8 264.82B 3.0% 5.5% 12.29B 2.57B 9.72B 5.13B

Key risks

  • Medical cost trend stays elevated longer than repricing can offset, keeping margins near 4%
  • Medicare Advantage rate notices, risk-adjustment (V28) changes, or star-rating losses compress government segment profits
  • Medicaid policy shifts and federal funding cuts reduce enrollment and squeeze state rate adequacy

Catalysts

  • 2027 commercial and MA bid repricing showing visible MLR improvement
  • Carelon Rx and CarelonServices growth lifting the share of higher-margin fee revenue

History

DatePriceIntrinsicMoSRating
2026-10-23$445.28 $442.04 -0.7% STRONG BUY
2026-09-03$405.84 $281.98 -30.5% BUY
2026-07-14$425.17 $447.38 +5.2% STRONG BUY
2026-06-23$395.10 $529.67 +34.1% STRONG BUY